A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Zachary A. Marcum, PharmD, PhD
Advertisement
Articles by Zachary A. Marcum, PharmD, PhD
Advertisement
Latest Updated Articles
- Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Published: March 27th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
3
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
4
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
5
